We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

1910:HKEXSamsonite Group S.A. Analysis

Data as of 2026-05-25 - not real-time

HK$14.63

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Samsonite (1910.HK) is trading at HK$14.63, which sits below its 20‑day (HK$14.54) and 50‑day (HK$15.20) simple moving averages and well under the 200‑day SMA of HK$17.48, confirming a bearish price structure. The RSI of 48 indicates neutral momentum, while the MACD histogram is positive, hinting at a modest short‑term bounce. Volume is on an upward trend, and the stock finds support around HK$13.65 with resistance near HK$15.39, suggesting limited upside in the near term.
On the fundamentals side, Samsonite delivers a solid 59.5% gross margin and a respectable 18% ROE, but its debt‑to‑equity ratio of 138% and net debt of roughly HK$1.7 bn raise balance‑sheet concerns. The forward P/E of 8.4 and a dividend yield of 5.4% (payout ~52%) provide an attractive income component, yet the DCF‑derived fair value of HK$3.60 flags a significant valuation gap. Analysts are overwhelmingly bullish with a “strong buy” consensus and a median price target of HK$21.22, implying a potential 44% upside. The stock’s beta of 0.62 and a 30‑day volatility of 45% indicate moderate market sensitivity, while the “Extreme Greed” sentiment index reflects a highly optimistic market backdrop. Overall, the company’s brand strength and cash‑flow generation support a long‑run case, but the current price appears stretched relative to intrinsic estimates. Its global footprint across Asia, North America, Europe and Latin America provides diversification that mitigates regional economic cycles.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support level
  • Bearish alignment with moving averages
  • Positive MACD histogram suggesting limited bounce

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst consensus strong‑buy with 44% upside
  • Attractive dividend yield and solid cash‑flow coverage
  • Low forward P/E indicating earnings‑based undervaluation

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • High leverage and DCF‑based overvaluation
  • Resilient brand portfolio and global diversification
  • Sustainable dividend payout supported by free cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth4.10%
Profit Margin7.73%
P/E Ratio9.0
ROE18.07%
ROA6.42%
Debt/Equity138.54
P/B Ratio1.6
Op. Cash FlowHK$583.2M
Free Cash FlowHK$428.8M

Technical Analysis

TrendBearish
RSI47.9
SupportHK$13.65
ResistanceHK$15.39
MA 20HK$14.54
MA 50HK$15.20
MA 200HK$17.48
MACDBullish
VolumeIncreasing
Fear & Greed Index91.8

Valuation

Fair ValueHK$3.60
Target PriceHK$21.13
Upside/Downside44.45%
GradeOvervalued
TypeValue
Dividend Yield5.40%

Risk Assessment

Beta0.62
Volatility45.04%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.